Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.83 +0.81 (+1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,277,029
Open 68.37
Bid (Size) 67.50 (1)
Ask (Size) 67.70 (1)
Prev. Close 67.02
Today's Range 67.74 - 68.50
52wk Range 52.65 - 76.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
The companies are still testing to see if their drug has a benefit on overall survival. 
Via Investor's Business Daily
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga

Performance

YTD
-2.16%
-2.16%
1 Month
-1.84%
-1.84%
3 Month
-5.95%
-5.95%
6 Month
-0.12%
-0.12%
1 Year
+20.46%
+20.46%

More News

Read More
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
Via FinancialNewsMedia
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via Benzinga
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
From AstraZeneca
Via Business Wire
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
Via Benzinga
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
From AstraZeneca
Via Business Wire
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Via Benzinga
What's Going On With AstraZeneca Stock Today?
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
From AstraZeneca
Via Business Wire
4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population
Via Benzinga
FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question
Via Benzinga
Exposures Product Safety
3 Forever Stocks to Buy With $100
Via The Motley Fool
Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories
Via Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
Via Benzinga
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Via The Motley Fool
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
Via The Motley Fool
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
Via Investor's Business Daily
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.